Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPJN0M)

Drug Name
PMID29671355-Compound-21 Drug Info
Cross-matching ID
PubChem CID
86295624
TTD Drug ID
DMPJN0M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histone deacetylase 9 (HDAC9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [1]
PMID29671355-Compound-73 DMCNF36 N. A. N. A. Patented [1]
TMP269 DMSMQE7 Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting Histone deacetylase 3 (HDAC3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CHR-3996 DMIXPNG Lymphoma 2A80-2A86 Phase 1/2 [3]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
PMID29671355-Compound-8 DM7YQJK N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 6 (HDAC6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Citarinostat DMQLODU Multiple myeloma 2A83 Phase 1 [4]
KA2507 DMW0H9Y Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 8 (HDAC8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NBM-BMX DM5OWXA Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 2 (HDAC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CHR-3996 DMIXPNG Lymphoma 2A80-2A86 Phase 1/2 [3]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 4 (HDAC4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-61 DMXH1G3 N. A. N. A. Patented [1]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [1]
PMID29671355-Compound-68b DMLGBR6 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 1 (HDAC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Cutaneous T-cell lymphoma 2B01 Approved [6]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [7]
Panobinostat DM58WKG Multiple myeloma 2A83 Approved [6]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [8]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [9]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [10]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [11]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [12]
MGCD-0103 DM726HX Non-small-cell lung cancer 2C25.Y Phase 2 [6]
Resminostat DMNE1FR Hepatocellular carcinoma 2C12.02 Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 10 (HDAC10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-8 DM7YQJK N. A. N. A. Patented [1]
PSAMMAPLIN A DM6T0IQ Discovery agent N.A. Investigative [14]
9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide DMVBCID Discovery agent N.A. Investigative [14]
7-Mercapto-heptanoic acid phenylamide DM4912P Discovery agent N.A. Investigative [15]
6-benzenesulfinylhexanoic acid hydroxamide DM2I95Z Discovery agent N.A. Investigative [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 11 (HDAC11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [1]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [1]
PMID29671355-Compound-36 DMQJ3TC N. A. N. A. Patented [1]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Histone deacetylase 7 (HDAC7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [1]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [1]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [1]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [1]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [1]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [1]
PMID29671355-Compound-45a DM5LYKR N. A. N. A. Patented [1]
TMP269 DMSMQE7 Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [1]
Histone deacetylase 10 (HDAC10) TTYHPU6 HDA10_HUMAN Inhibitor [1]
Histone deacetylase 11 (HDAC11) TT8K17W HDA11_HUMAN Inhibitor [1]
Histone deacetylase 2 (HDAC2) TTSHTOI HDAC2_HUMAN Inhibitor [1]
Histone deacetylase 3 (HDAC3) TT4YWTO HDAC3_HUMAN Inhibitor [1]
Histone deacetylase 4 (HDAC4) TTTQGH8 HDAC4_HUMAN Inhibitor [1]
Histone deacetylase 6 (HDAC6) TT5ZKDI HDAC6_HUMAN Inhibitor [1]
Histone deacetylase 7 (HDAC7) TTMUEK1 HDAC7_HUMAN Inhibitor [1]
Histone deacetylase 8 (HDAC8) TTT6LFV HDAC8_HUMAN Inhibitor [1]
Histone deacetylase 9 (HDAC9) TT8M4E1 HDAC9_HUMAN Inhibitor [1]

References

1 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
2 Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25.
3 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
6 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
7 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
9 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
10 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
11 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
12 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
13 2011 Pipeline of 4SC AG.
14 Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116.
15 Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32.
16 Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5.